Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASCEND: A Randomized, Double Blind, Sham-Controlled, Multi-Center Phase I/II Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs

NCT06615505 is registered in ClinicalTrials.gov with VIVEX Biologics, Inc. as lead sponsor.

NCT NCT06615505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASCEND: A Randomized, Double Blind, Sham-Controlled, Multi-Center Phase I/II Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
Lead sponsor
VIVEX Biologics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 4, 2024
Completion date
November 30, 2027
Enrollment
121 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative disc disease, disc degeneration, lumbar discogenic pain